Cardiovascular Disease Preclinical Research: Recent Update

Ace Therapeutics is proud to announce the launch of its cardiovascular disease model development services aiming to accelerate the study of cardiovascular diseases and drug discovery.

Ace Therapeutics, a contract research organization engaged in cardiovascular disease research, is proud to announce the launch of its cardiovascular disease model development services, aiming to empower researchers and pharmaceutical companies with advanced tools and models to accelerate the study of cardiovascular diseases and drug discovery.

Cardiovascular disease (CVD) remains a leading cause of morbidity and mortality worldwide, underscoring the urgent need for innovative research and therapeutic solutions. Cardiovascular disease models are essential tools used in the research of heart-related conditions. These models can be biochemical, physiological, computational, or clinical, and they aim to simulate various aspects of cardiovascular health, disease progression, and responses to interventions. Recent years have witnessed the development of a series of disease models for cardiovascular disease research, such as cardiac organoid models and cardiomyocyte models, which greatly contribute to the basic research on the pathogenic mechanisms of various cardiovascular diseases and the development of new therapeutic methods.

The construction of cardiovascular disease models requires first analysing the disease process and determining the type of model construction. In addition to traditional animal models, a series of other disease models have been developed in recent years for cardiovascular disease research, such as cardiac organoid models and cardiomyocyte models. These various types of cardiovascular disease models have greatly contributed to basic research on the pathogenic mechanisms of various cardiovascular diseases and the development of new therapeutic methods.

Ace Therapeutics’ new suite of model development services is designed to provide customized, reliable, and reproducible preclinical models that closely mimic various cardiovascular conditions. In addition to a variety of experimental animals including mice, rats, rabbits, and monkeys, Ace Therapeutics can assist worldwide clients in constructing custom animal models using techniques such as environmental enrichment, gene editing, dietary modifications, or drug therapies. Moreover, the company can also provide researchers with cardiac organoid models and human induced pluripotent stem cell (hiPSC) models to support their research into the mechanisms of cardiovascular disease and facilitate the development of effective new drugs and cell therapies. Ultimately, these diverse models are developed to bridge the gap between laboratory research and clinical application for most cardiovascular diseases such as atherosclerosis, hypertension, thrombosis, heart failure, and cardiovascular infection.

Utilizing a range of specialized animal-specific hematology analyzers, biochemical analyzers, small animal PET/MRI imaging systems, and other instruments, Ace Therapeutics will conduct modeling, drug administration, sampling, and testing of physiological and biochemical indices in common laboratory animals for clients. These services are dedicated to advancing basic research, diagnostic method development, and drug development for cardiovascular diseases.

About Ace Therapeutics

Ace Therapeutics is a contract research service provider dedicated to providing a full range of research services for cardiovascular diseases. From disease model development to preclinical research support, Ace Therapeutics’ well-established research technology platforms enable its expert team to conduct research on a wide range of cardiovascular diseases, advancing the research and development in this field.